US EditionIsomorphic Labs Secures $600M to Advance AI-Powered Drug Discovery
- Isomorphic Labs, an AI-based drug discovery company spun out of Google DeepMind and based in London, raised $600 million in its first external funding round.
- Founded in 2021 by Sir Demis Hassabis to develop treatments for millions of patients worldwide, Isomorphic Labs leverages DeepMind's AlphaFold software to advance its AI drug design engine.
- This funding will accelerate research and development efforts, advance Isomorphic Labs' AI drug design engine, and support the company's internal drug pipeline focused on oncology and immunology, including small molecule programs developed through collaborations.
- Isomorphic Labs has collaborations with Eli Lilly and Novartis, potentially generating up to $3 billion in milestone payments; Eli Lilly paid $45 million upfront with potential milestone payments up to $1.7 billion, while Novartis paid $37.5 million upfront with potential milestone payments up to $1.2 billion, also agreeing last month to add three additional programs to their collaboration.
- Led by Sir Demis Hassabis, Isomorphic Labs expects to use the new capital to expand its staff, attract top-tier talent, advance its programs into clinical development, and potentially have AI-designed drugs in clinical trials by the end of 2025, furthering its mission to solve all disease with AI.
42 Articles
42 Articles
An AI Biotech Hauls In $600M, Plus More Funding Highlights to Close 1Q 2025
Isomorphic Labs’ financing led the way for first quarter 2025 financings, but it comes amid headwinds for the biotech sector. Biotech financing activity has been slowing down, analysts say. The post An AI Biotech Hauls In $600M, Plus More Funding Highlights to Close 1Q 2025 appeared first on MedCity News.
Demis Hassabis on Isomorphic’s $600 million raise, AI, and healthcare’s future
What if it’s not "just a game"? In AI, games are more than just fun—they can reconceive what’s possible. Demis Hassabis, cofounder of DeepMind and 2024 Nobel Laureate, knows this firsthand. In 2016, after AlphaGo—the AI program developed to play the ancient Chinese game of Go—defeated world champion Lee Sedol, Hassabis saw a new horizon for AI. The victory wasn’t just about beating an 18-time international champion, it was a demonstration of AI…
Alphabet’s AI drug discovery platform Isomorphic Labs raises $600M from Thrive
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised external capital for the first time. The $600 million round was led by Thrive Capital, with participation from GV and existing investor Alphabet, Google’s parent, it said. The funding will accelerate further development of Isomorphic’s AI drug design engine and support the company’s goal of bringing its discovered drugs to clinical tria…
TechCrunch
Latest Nigerian NewsAlphabet's AI drug discovery platform Isomorphic Labs raises $600M from Thrive
Isomorphic Labs, the AI drug discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600
Coverage Details
Bias Distribution
- 67% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
